StockNews.AI
JAGX
StockNews.AI
173 days

Jaguar Health Adopts Limited Duration Stockholder Rights Plan to Ensure Stockholders Can Realize Long-Term Value

1. Jaguar expects 2025 trial results for crofelemer's impact on rare diseases. 2. Company has received an acquisition interest amid ongoing stock price dislocation.

2m saved
Insight
Article

FAQ

Why Bullish?

The anticipated trial results and acquisition interest may boost investor confidence, improving stock performance.

How important is it?

The company's trial outcomes and acquisition interest are crucial to JAGX's future valuation.

Why Long Term?

Positive clinical trial outcomes might enhance market perception over the next few quarters.

Related Companies

ACSTWLDSVYGR
Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer Jaguar has received an indication of interest to acquire the Company SAN FRANCISCO, CA / ACCESS Newswire / February 27, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights plan (the "Rights Plan"). "Jaguar, which, like many other biotechnology companies, continues to experience a significant and ongoing dislocation in the trading price of its common stock, has received an indication of interest to acquire the Company.

Related News